MNKD (MannKind) Future Price to Earnings

Official company branding of MannKind (MNKD)

MannKind Corporation (MNKD) is scaling its inhalation systems and pivoting toward pulmonary hypertension therapy. The issuer's forward P/E visualizes this trend, where the 84.00 mark serves as the current indicator. Royalties and a diversified pipeline support this growth, effectively mitigating risks. The ecosystem surrounding Afrezza needle-free insulin ensures customer loyalty, creating unique product value for diabetes patients.

mannkindcorp.com - MNKD Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for mannkindcorp.com (MNKD)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:MNKD Afrezza
Brand item of MannKind Corporation

Investors value MannKind Corporation (MNKD) for the steady growth in demand for innovative inhalation drugs. The forward P/E measures the ratio of the current share price to expected earnings, determining the extent of the premium paid for future income. By analyzing the company's expected NTM P/E on GURU.Markets, one can assess the fairness of its market value. Low values signal undervaluation, while high values reflect inflated expectations. This allows for the precise synchronization of the entry point with the potential for customer base expansion.

Competitors of MannKind Corporation

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|LQDA (Liquidia Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio glpg.com GLPG|Future Price to Earnings ANI Pharmaceuticals, Inc. (ANIP)|AMPH (Amphastar Pharmaceuticals, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Pacira BioSciences, Inc. PCRX|Forward P/E Multiple ARS Corp SPRY|Theravance Biopharma - Forward P/E Multiple|Forward Price to Earnings Multiple Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Future Price to Earnings|Projected Price to Earnings Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forward P/E Multiple|Price to Future Earnings Ratio SXTC (China SXT Pharmaceuticals)|Forward P/E Multiple EPRX|Forward P/E Multiple bioharvest.com (BHST)|Future Price to Earnings Invizyne Technologies EXOZ|ORMP: Price to Future Earnings Ratio|ENTX: Projected Price to Earnings|HYFT: Future Price to Earnings|ABVC BioPharma Inc. (ABVC) - Future Price to Earnings|cumberlandpharma.com (CPIX) - Forward P/E Multiple|QNTM (Quantum BioPharma) - Forward P/E Multiple|FGEN: Future Price to Earnings Multiple|Forward P/E Multiple TELO|Forward P/E Multiple Rani Therapeutics Holdings (RANI)|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP